Clascoterone (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Clascoterone" in English language version.
Last modified:
Ref.Un. Ref.Website
Global rank
English rank
15th place
8th place
4th place
4th place
1st place
1st place
low place
low place
low place
low place
low place
low place
4,353rd place
2,806th place
546th place
310th place
low place
low place
66th place
34th place
182nd place
172nd place
dermatologytimes.com (Global: low place; English: low place)
- Hebebrand M (12 January 2026). "Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results". Dermatology Times. Retrieved 12 January 2026.
doi.org (Global: 2nd place; English: 2nd place)
- Barbieri JS (June 2020). "A New Class of Topical Acne Treatment Addressing the Hormonal Pathogenesis of Acne". JAMA Dermatology. 156 (6): 619–620. doi:10.1001/jamadermatol.2020.0464. ISSN 2168-6068. PMID 32320045. S2CID 216075268.
- Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. (April 2020). "Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials". JAMA Dermatology. 156 (6): 621–630. doi:10.1001/jamadermatol.2020.0465. PMC 7177662. PMID 32320027.
- Celasco G, Moro L, Bozzella R, Ferraboschi P, Bartorelli L, Quattrocchi C, et al. (2004). "Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist". Arzneimittel-Forschung. 54 (12): 881–886. doi:10.1055/s-0031-1297043. PMID 15646372. S2CID 36709725.
- Celasco G, Moroa L, Bozzella R, Ferraboschi P, Bartorelli L, Di Marco R, et al. (2005). "Pharmacological profile of 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity". Arzneimittel-Forschung. 55 (10): 581–587. doi:10.1055/s-0031-1296908. PMID 16294504. S2CID 35386850.
- Lerner LJ (1975). "Androgen antagonists". Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology. 1 (2): 217–231. doi:10.1016/0306-039x(75)90006-9. PMID 772705.
- Der Sarkissian SA, Sun HY, Sebaratnam DF (August 2020). "Cortexolone 17 α-proprionate for hidradenitis suppurativa". Dermatologic Therapy. 33 (6) e14142. doi:10.1111/dth.14142. PMID 32761708. S2CID 221036602.
europa.eu (Global: 62nd place; English: 100th place)
ema.europa.eu
- "Winlevi Authorisation Details". European Medicines Agency. 17 October 2025. Retrieved 25 March 2026.
- "Winlevi EPAR". European Medicines Agency (EMA). 30 April 2025. Retrieved 2 May 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Winlevi Authorisation Details". European Medicines Agency. 17 October 2025. Retrieved 25 March 2026.
fda.gov (Global: 470th place; English: 329th place)
accessdata.fda.gov
- "Drug Approval Package: Winlevi". U.S. Food and Drug Administration (FDA). 29 September 2020. Retrieved 15 June 2025.
fda.gov
- "Drug Trial Snapshot: Winlevi". U.S. Food and Drug Administration (FDA). 26 August 2020. Archived from the original on 29 October 2020. Retrieved 10 September 2020.
This article incorporates text from this source, which is in the public domain.
fda.report (Global: low place; English: low place)
- "New Drug Therapy Approvals 2020" (PDF). U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021. This article incorporates text from this source, which is in the public domain.
hdl.handle.net (Global: 66th place; English: 34th place)
- "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3): 106. 2019. hdl:10665/330879.
hpfb-dgpsa.ca (Global: low place; English: low place)
dhpp.hpfb-dgpsa.ca
- "Details for: Winlevi". Health Canada. 8 September 2023. Retrieved 3 March 2024.
- "Summary Basis of Decision for Winlevi". Health Canada. 30 August 2023. Retrieved 4 October 2023.
- "Details for: Winlevi". Health Canada. 8 September 2023. Retrieved 4 October 2023.
mdedge.com (Global: low place; English: low place)
- Kircik LH (July 2019). "What's new in the management of acne vulgaris". Cutis. 104 (1): 48–52. PMID 31487336.
nih.gov (Global: 5th place; English: 5th place)
pubmed.ncbi.nlm.nih.gov
- Kircik LH (July 2019). "What's new in the management of acne vulgaris". Cutis. 104 (1): 48–52. PMID 31487336.
- Rosette C, Rosette N, Mazzetti A, Moro L, Gerloni M (February 2019). "Cortexolone 17α-Propionate (Clascoterone) is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro". Journal of Drugs in Dermatology. 18 (2): 197–201. PMID 30811143.
- Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M (May 2019). "Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro". Journal of Drugs in Dermatology. 18 (5): 412–418. PMID 31141847.
- Barbieri JS (June 2020). "A New Class of Topical Acne Treatment Addressing the Hormonal Pathogenesis of Acne". JAMA Dermatology. 156 (6): 619–620. doi:10.1001/jamadermatol.2020.0464. ISSN 2168-6068. PMID 32320045. S2CID 216075268.
- Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. (April 2020). "Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials". JAMA Dermatology. 156 (6): 621–630. doi:10.1001/jamadermatol.2020.0465. PMC 7177662. PMID 32320027.
- Celasco G, Moro L, Bozzella R, Ferraboschi P, Bartorelli L, Quattrocchi C, et al. (2004). "Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist". Arzneimittel-Forschung. 54 (12): 881–886. doi:10.1055/s-0031-1297043. PMID 15646372. S2CID 36709725.
- Celasco G, Moroa L, Bozzella R, Ferraboschi P, Bartorelli L, Di Marco R, et al. (2005). "Pharmacological profile of 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity". Arzneimittel-Forschung. 55 (10): 581–587. doi:10.1055/s-0031-1296908. PMID 16294504. S2CID 35386850.
- Lerner LJ (1975). "Androgen antagonists". Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology. 1 (2): 217–231. doi:10.1016/0306-039x(75)90006-9. PMID 772705.
- Der Sarkissian SA, Sun HY, Sebaratnam DF (August 2020). "Cortexolone 17 α-proprionate for hidradenitis suppurativa". Dermatologic Therapy. 33 (6) e14142. doi:10.1111/dth.14142. PMID 32761708. S2CID 221036602.
dailymed.nlm.nih.gov
- "Winlevi- clascoterone cream". DailyMed. 2 January 2025. Retrieved 15 June 2025.
ncbi.nlm.nih.gov
- Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. (April 2020). "Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials". JAMA Dermatology. 156 (6): 621–630. doi:10.1001/jamadermatol.2020.0465. PMC 7177662. PMID 32320027.
pubchem.ncbi.nlm.nih.gov
prnewswire.com (Global: 546th place; English: 310th place)
- "Cassiopea Receives FDA Approval for Winlevi (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptor" (Press release). Cassiopea. 27 August 2020. Retrieved 15 June 2025 – via PR Newswire.
semanticscholar.org (Global: 15th place; English: 8th place)
api.semanticscholar.org
- Barbieri JS (June 2020). "A New Class of Topical Acne Treatment Addressing the Hormonal Pathogenesis of Acne". JAMA Dermatology. 156 (6): 619–620. doi:10.1001/jamadermatol.2020.0464. ISSN 2168-6068. PMID 32320045. S2CID 216075268.
- Celasco G, Moro L, Bozzella R, Ferraboschi P, Bartorelli L, Quattrocchi C, et al. (2004). "Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist". Arzneimittel-Forschung. 54 (12): 881–886. doi:10.1055/s-0031-1297043. PMID 15646372. S2CID 36709725.
- Celasco G, Moroa L, Bozzella R, Ferraboschi P, Bartorelli L, Di Marco R, et al. (2005). "Pharmacological profile of 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04), a new androgen antagonist with antigonadotropic activity". Arzneimittel-Forschung. 55 (10): 581–587. doi:10.1055/s-0031-1296908. PMID 16294504. S2CID 35386850.
- Der Sarkissian SA, Sun HY, Sebaratnam DF (August 2020). "Cortexolone 17 α-proprionate for hidradenitis suppurativa". Dermatologic Therapy. 33 (6) e14142. doi:10.1111/dth.14142. PMID 32761708. S2CID 221036602.
springer.com (Global: 182nd place; English: 172nd place)
adisinsight.springer.com
tga.gov.au (Global: 4,353rd place; English: 2,806th place)
- "Winlevi APMDS". Therapeutic Goods Administration (TGA). 17 May 2024. Retrieved 10 June 2024.
web.archive.org (Global: 1st place; English: 1st place)
- "Drug Trial Snapshot: Winlevi". U.S. Food and Drug Administration (FDA). 26 August 2020. Archived from the original on 29 October 2020. Retrieved 10 September 2020. This article incorporates text from this source, which is in the public domain.